GlaxoSmithKline (GSK) has appointed Jonathan Symonds, formerly CFO at both Philip Hampton and AstraZeneca, as chairman, to replace outgoing Novartis, according to reports. The pharmaceutical company is currently preparing for a consumer health joint venture with Pfizer, as it splits its pharma and consumer health businesses. Symonds, currently deputy group chairman at HSBC, has overseen several big deals and has knowledge of the life sciences industry. GSK said it will make an announcement on the appointment in "due course".
GlaxoSmithKline (GSK) has appointed Jonathan Symonds, formerly CFO at both Novartis and AstraZeneca, as chairman, to replace outgoing Philip Hampton, according to reports. The pharmaceutical company is currently preparing for a consumer health joint venture with Pfizer, as it splits its pharma and consumer health businesses. Symonds, currently deputy group chairman at HSBC, has overseen several big deals and has knowledge of the life sciences industry. GSK said it will make an announcement on the appointment in "due course".